[SCHEDULE 13D/A] Great Elm Group, Inc. Amended Major Shareholder Report

Great Elm Group, Inc. (GEG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GREAT ELM GROUP REPORTS FISCAL 2026 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS – Fiscal 2026 Net Loss of Approximately $35 Million, Driven Primarily by GECC Share Price Decline – – Fourth Quarter Total Revenue Increased 88% from the Prior-Year Period – – Nearly $

Moderna (MRNA) fell 17% after phase 3 data for its cancer vaccine showed less improvement than expected. Analysts are divided on its potential, with some citing concerns over efficacy, cost, and complexity. Merck's (MRK) Keytruda was part of the trial.

Franklin Templeton has cleared the final regulatory hurdle to launch two ETFs that convert stock dividends into bitcoin. The Franklin US Equity Bitcoin DRIP Index ETF (FBEQ) and the Franklin US Innovation Bitcoin DRIP Index ETF will start trading on October 27. The funds allocate 95% to stocks and 5% to bitcoin, reinvesting dividends into bitcoin. FBEQ tracks the VettaFi US Large-Cap 500 Bitcoin DRIP Index and has a 0.09% expense ratio.

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

Bristol Myers Squibb (BMY) shared Phase 1 data for zolacabtagene autoleucel (zola-cel) in MS patients, showing promising results. Separately, BMY expanded its AI collaboration with Tempus (TEM) through 2031. BMY stock is down 2.30%, TEM up 1.54%.

Bristol Myers Squibb presented interim Phase 1 study results for zolacabtagene autoleucel (zola-cel) in multiple sclerosis patients. The study showed a consistent safety profile and early efficacy signals. 60 patients remained off disease-modifying therapies, with most adverse events being brief and reversible. The company plans to advance zola-cel in autoimmune disease treatments.